AEON Biopharma, Inc.

AEON Biopharma, Inc. filed an amended quarterly report on Form 10-Q/A with the SEC on March 3, 2022, under CIK 0001837607, in connection with its pending business combination with Priveterra Acquisition Corp, a blank-check company that completed its initial public offering in 2021 and listed on Nasdaq under the ticker PAQC. Priveterra was sponsored by Priveterra Holdings LLC and concentrated its target search within the healthcare and biopharmaceutical sector. AEON Biopharma is a clinical-stage company advancing botulinum-toxin-derived therapeutics for neurological and central nervous system conditions. The 10-Q/A amendment was submitted during the pre-close phase of the de-SPAC transaction. Sign up on SpacDesk for complete filing history, deal status tracking, and comparable transaction data.